Loading...

Nola Hylton, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentRadiology
Address2200 Post Street
San Francisco CA 94115
Phone415-885-7511
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Academy of Radiology Research 2013Distinguished Investigator
    Susan G. Komen for the Cure's2010Scientific Advisory Council
    Komen2010Cure Scholar Award
    American College of Radiology Imaging Network2003Outstanding Contribution Award
    American Cancer Society 2003Research Scholar
    Radiology 1987  - 1988Editor's Recognition Award with Distinction
    Stanford University1979Graduate Professional Opportunities Program Fellowship
    Bell Telephone Laboratories 1975Undergraduate Fellowship

    Collapse Overview 
    Collapse Overview
    Nola Hylton, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging, Co-Director of the Breast Cancer Research Interest Group, and Director of the Breast Imaging Research Group at the University of California, San Francisco. Dr. Hylton received her BS in Chemical Engineering from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1979, and she obtained her PhD in Applied Physics from Stanford University, California in 1985.

    Dr. Hylton has been integrally involved in the development of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer. Dr. Hylton is an internationally known leader in the field of breast MRI for more than 20 years. Her search has addressed the clinical optimization and evaluation of breast MRI technology. Her current research program focuses on the development and clinical evaluation of MRI techniques for characterizing breast cancers and assessing their response to treatment. Her laboratory collaborates closely with a multi-disciplinary team of radiologists, surgeons, oncologists, and science researchers nation wide. This is to optimize MRI techniques for the clinical management of breast cancer patients.

    Dr. Hylton is among the first group of scholars named the Susan G. Komen for the Cure’s Scientific Advisory Council. She served as co-leader for the DHHS office of Women’s Health International Working Group where she identified and addressed barriers to clinical dissemination of breast MRI. She also served as the institutional Principal Investigator of the NCI International Breast MRI Consortium, which is the first large multi-center clinical trial evaluating breast MRI for breast cancer diagnosing and staging.

    Dr. Hylton has over 80 published research articles, and she has written 13 book chapters and over 130 abstracts.

    Expertise:
    Breast Imaging

    Specialty:
    Breast cancer imaging, breast MRI

    Professional Interests:
    Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging

    Education and Training:
    • Bachelor of Science: Massachusetts Institute of Technology (MIT), Cambridge - Chemical Engineering
    • Doctor of Philosophy: Stanford University, California - Applied Physics


    Collapse Research 
    Collapse Research Activities and Funding
    Quantitative Imaging for Assessing Breast Cancer Response to Treatment
    NIH U01CA151235Sep 26, 2011 - Aug 31, 2016
    Role: Principal Investigator
    Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials
    NIH/NCI R01CA132870Apr 25, 2008 - Jun 30, 2020
    Role: Principal Investigator
    MRI For Staging DCIS and Assessing Response to Treatment
    NIH R01CA116182Aug 23, 2006 - Jul 31, 2013
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH/NCI U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Co-Investigator
    Anatomic and Biologic Staging of Breast Disease with MRI
    NIH R01CA069587Jan 15, 1997 - Feb 28, 2012
    Role: Principal Investigator
    NMR Imaging and Spectroscopy
    NIH P41RR008079Jun 1, 1993 - May 31, 2013
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN. Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices. Radiology. 2017 Oct 25; 170811. PMID: 29072981.
      View in: PubMed
    2. Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B. Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med. 2017 Sep 14. PMID: 28913930.
      View in: PubMed
    3. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton N. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 Jun; 17(3):e155-e159. PMID: 28110902.
      View in: PubMed
    4. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 Jul; 46(1):290-302. PMID: 27981651.
      View in: PubMed
    5. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. PMID: 28066808.
      View in: PubMed
    6. Farahani K, Kalpathy-Cramer J, Chenevert TL, Rubin DL, Sunderland JJ, Nordstrom RJ, Buatti J, Hylton N. Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network. Tomography. 2016 Dec; 2(4):242-249. PMID: 28798963.
      View in: PubMed
    7. Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res. 2016 Oct 15; 76(20):5933-5944. PMID: 27527559.
      View in: PubMed
    8. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton N, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    9. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton N, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    10. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF. Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women. Cancer Epidemiol Biomarkers Prev. 2016 Jul; 25(7):1151-7. PMID: 27197299; PMCID: PMC4930720 [Available on 07/01/17].
    11. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton N, et al. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 Oct; 44(4):846-55. PMID: 27008431.
      View in: PubMed
    12. Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton N. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 Sep; 44(3):610-9. PMID: 26949897; PMCID: PMC4983524 [Available on 09/01/17].
    13. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. PMID: 26886725; PMCID: PMC4757528.
    14. Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL. Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res. 2016 Jan 15; 22(2):284-90. PMID: 26773162; PMCID: PMC4717912 [Available on 01/15/17].
    15. Hylton N, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016 Apr; 279(1):44-55. PMID: 26624971; PMCID: PMC4819899 [Available on 04/01/17].
    16. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Res. 2015 Jul 16; 17:95. PMID: 26174168; PMCID: PMC4502611.
    17. Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. PMID: 26244152; PMCID: PMC4517335.
    18. Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF. Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res. 2015 Jun 04; 17:77. PMID: 26041651; PMCID: PMC4468804.
    19. Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD. Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS One. 2015; 10(3):e0122151. PMID: 25816249; PMCID: PMC4376686.
    20. Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N. Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. J Magn Reson Imaging. 2015 Oct; 42(4):908-19. PMID: 25758543; PMCID: PMC4629811 [Available on 10/01/16].
    21. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
    22. Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN. Extra-mammary findings on breast MRI: a pictorial review. Clin Imaging. 2015 Jul-Aug; 39(4):547-52. PMID: 25772531.
      View in: PubMed
    23. Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B. Lesion morphology on breast MRI affects targeted ultrasound correlation rate. Eur Radiol. 2015 May; 25(5):1279-84. PMID: 25500714.
      View in: PubMed
    24. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83. PMID: 24807204.
      View in: PubMed
    25. Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7. PMID: 24772216; PMCID: PMC3998684.
    26. Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Transl Oncol. 2014 Feb; 7(1):65-71. PMID: 24772209; PMCID: PMC3998685.
    27. Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galb N CJ, Meyer CR, Ross BD. Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol. 2014 Feb; 7(1):101-10. PMID: 24772213; PMCID: PMC3998680.
    28. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100. PMID: 24772212; PMCID: PMC3998689.
    29. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82. PMID: 24347097; PMCID: PMC4507716.
    30. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653. PMID: 24324712; PMCID: PMC3852736.
    31. Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. J Magn Reson Imaging. 2014 Sep; 40(3):674-81. PMID: 24214467; PMCID: PMC4014534.
    32. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 2013 Nov-Dec; 19(6):650-8. PMID: 24165314; PMCID: PMC4036640.
    33. McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13. PMID: 24719242; PMCID: PMC3983569.
    34. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83. PMID: 23933948; PMCID: PMC3960004.
    35. Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46. PMID: 23928243.
      View in: PubMed
    36. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61. PMID: 23878283; PMCID: PMC3807081.
    37. Mukhtar RA, Yau C, Rosen M, Tandon VJ, Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. PMID: 23780381; PMCID: PMC3824937.
    38. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82. PMID: 23701101.
      View in: PubMed
    39. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9. PMID: 23701102; PMCID: PMC4511702.
    40. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013 Aug; 13(4):280-6. PMID: 23664819; PMCID: PMC4441524.
    41. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969. PMID: 23667451; PMCID: PMC3646993.
    42. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9. PMID: 23570936; PMCID: PMC4507576.
    43. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83. PMID: 23436342; PMCID: PMC3939707.
    44. Hylton N. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 2013 Jan; 266(1):367. PMID: 23390630.
      View in: PubMed
    45. Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM. Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Res. 2012 Jul 13; 14(4):R107. PMID: 22800711; PMCID: PMC3680938.
    46. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72. PMID: 22623692; PMCID: PMC3359517.
    47. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8. PMID: 22652232.
      View in: PubMed
    48. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152; PMCID: PMC3434983.
    49. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
    50. Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. Acad Radiol. 2012 May; 19(5):526-34. PMID: 22197382; PMCID: PMC3319166.
    51. Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magn Reson Imaging. 2011 Nov; 29(9):1215-21. PMID: 21920686; PMCID: PMC3199288.
    52. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33. PMID: 21843942; PMCID: PMC4087114.
    53. McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. NMR Biomed. 2011 Jul; 24(6):712-20. PMID: 21692116; PMCID: PMC4509744.
    54. Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD. Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model. Magn Reson Med. 2011 Dec; 66(6):1722-30. PMID: 21688315; PMCID: PMC3186821.
    55. Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N. Quantification of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging. 2011 May; 33(5):1229-34. PMID: 21509883; PMCID: PMC3081108.
    56. Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN. MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy. AJR Am J Roentgenol. 2011 Apr; 196(4):W471-5. PMID: 21427313.
      View in: PubMed
    57. Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN. Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions? Acad Radiol. 2011 Jun; 18(6):716-21. PMID: 21420333; PMCID: PMC4506794.
    58. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr; 3(4):490-6. PMID: 21416100; PMCID: PMC3698966.
    59. Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar; 11(1):33-8. PMID: 21421520; PMCID: PMC4508001.
    60. Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Pettee Gabriel K, Kriska A, Ruder EH, Fang CY, Barton BA. Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study. Cancer Epidemiol Biomarkers Prev. 2010 Jun; 19(6):1545-56. PMID: 20501774; PMCID: PMC2883023.
    61. Le-Petross HC, Hylton N. Role of breast MR imaging in neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2010 May; 18(2):249-58, viii-ix. PMID: 20494310.
      View in: PubMed
    62. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. PMID: 19728082; PMCID: PMC4087110.
    63. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
    64. Hylton NM. Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment? Radiology. 2009 Aug; 252(2):330-1. PMID: 19703876.
      View in: PubMed
    65. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Shepherd J, Gibbs J, Fan B, Noworolski S, Hylton N. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging. 2010 Jan; 28(1):8-15. PMID: 19631485; PMCID: PMC4087111.
    66. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. PMID: 19440188.
      View in: PubMed
    67. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9. PMID: 19388114; PMCID: PMC4511711.
    68. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
      View in: PubMed
    69. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008 Jul; 248(1):79-87. PMID: 18566170.
      View in: PubMed
    70. Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol. 2008 Jun; 190(6):1630-6. PMID: 18492917.
      View in: PubMed
    71. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton N, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008 Feb 10; 26(5):791-7. PMID: 18258988.
      View in: PubMed
    72. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. PMID: 17968965; PMCID: PMC3024590.
    73. Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, Hylton NM. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med. 2007 Sep; 58(3):572-81. PMID: 17685424; PMCID: PMC4508009.
    74. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007 Apr; 25(3):319-27. PMID: 17371720.
      View in: PubMed
    75. Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM. Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2007 Jan; 25(1):82-8. PMID: 17173311.
      View in: PubMed
    76. Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006 Oct; 192(4):520-4. PMID: 16978965; PMCID: PMC4087109.
    77. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006 Oct 01; 24(28):4603-10. PMID: 17008702; PMCID: PMC4087112.
    78. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006 Aug; 14(3):383-9, vii. PMID: 17098179.
      View in: PubMed
    79. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006 Jul 10; 24(20):3293-8. PMID: 16829653.
      View in: PubMed
    80. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006 Jan; 238(1):42-53. PMID: 16373758.
      View in: PubMed
    81. Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol. 2005 Oct 01; 92(1):9-15; discussion 15-6. PMID: 16180217.
      View in: PubMed
    82. Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct; 22(4):511-9. PMID: 16161072.
      View in: PubMed
    83. Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis CA. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol. 2005 Oct 01; 92(1):32-8. PMID: 16180227.
      View in: PubMed
    84. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt. 2005 Sep-Oct; 10(5):051503. PMID: 16292947.
      View in: PubMed
    85. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. PMID: 15908529.
      View in: PubMed
    86. Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol. 2005 Jun; 40(6):363-7. PMID: 15905723.
      View in: PubMed
    87. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005 May 01; 103(9):1898-905. PMID: 15800894.
      View in: PubMed
    88. Hylton N. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J Clin Oncol. 2005 Mar 10; 23(8):1678-84. PMID: 15755976.
      View in: PubMed
    89. Li KL, Zhu X, Hylton N, Jahng GH, Weiner MW, Schuff N. Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI. Magn Reson Med. 2005 Mar; 53(3):511-8. PMID: 15723393; PMCID: PMC1941668.
    90. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 08; 292(22):2735-42. PMID: 15585733.
      View in: PubMed
    91. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Lobo C, Demicco E, Watkins M, Shepherd J, Gibbs J, Hylton N. Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc. 2004; 3:1667-70. PMID: 17272023.
      View in: PubMed
    92. Hylton NM. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. AJR Am J Roentgenol. 2003 Sep; 181(3):677-8. PMID: 12933458.
      View in: PubMed
    93. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003 May; 10(4):381-8. PMID: 12734086.
      View in: PubMed
    94. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002 Nov; 179(5):1193-9. PMID: 12388497.
      View in: PubMed
    95. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer. 2002 Jun; 9(2):141-53. PMID: 12121836.
      View in: PubMed
    96. Partridge SC, McKinnon GC, Henry RG, Hylton NM. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging. 2001 Oct; 14(4):433-8. PMID: 11599068.
      View in: PubMed
    97. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. PMID: 11456056.
      View in: PubMed
    98. Kinkel K, Hylton NM. Challenges to interpretation of breast MRI. J Magn Reson Imaging. 2001 Jun; 13(6):821-9. PMID: 11382939.
      View in: PubMed
    99. Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, Barclay J, Schnall MD. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging. 2001 Jun; 13(6):889-95. PMID: 11382949.
      View in: PubMed
    100. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am. 2001 May; 9(2):321-32, vi. PMID: 11493422.
      View in: PubMed
    101. Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000 Dec; 175(6):1577-84. PMID: 11090379.
      View in: PubMed
    102. Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep. 2000 Nov; 2(6):572-81. PMID: 11122895.
      View in: PubMed
    103. Hylton NM. Suspension of breast-feeding following gadopentetate dimeglumine administration. Radiology. 2000 Aug; 216(2):325-6. PMID: 10924547.
      View in: PubMed
    104. Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol. 2000 Jul; 175(1):35-43. PMID: 10882243.
      View in: PubMed
    105. Hylton N. Dedicated Breast MRI Systems Working Group report. J Magn Reson Imaging. 1999 Dec; 10(6):1006-9. PMID: 10581519.
      View in: PubMed
    106. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am. 1999 May; 7(2):411-20, x. PMID: 10382170.
      View in: PubMed
    107. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999 Jan; 17(1):110-9. PMID: 10458224.
      View in: PubMed
    108. Partridge SC, Heumann EJ, Hylton NM. Semi-automated analysis for MRI of breast tumors. Stud Health Technol Inform. 1999; 62:259-60. PMID: 10538368.
      View in: PubMed
    109. Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J. 1999 Jan; 5(1):13-21. PMID: 11348250.
      View in: PubMed
    110. Hylton NM, Kinkel K. Technical aspects of breast magnetic resonance imaging. Top Magn Reson Imaging. 1998 Feb; 9(1):3-16. PMID: 9617899.
      View in: PubMed
    111. Bourne MW, Margerun L, Hylton N, Campion B, Lai JJ, Derugin N, Higgins CB. Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body. J Magn Reson Imaging. 1996 Mar-Apr; 6(2):3O5-1O. PMID: 9132094.
      View in: PubMed
    112. Hylton NM, Frankel SD. Imaging techniques for breast MR imaging. Magn Reson Imaging Clin N Am. 1994 Nov; 2(4):511-25. PMID: 7489305.
      View in: PubMed
    113. Hylton N, Simovsky I, Li AJ, Hale JD. Impact of section doubling on MR angiography. Radiology. 1992 Dec; 185(3):899-902. PMID: 1438782.
      View in: PubMed
    114. Hylton NM, Du LN, Winkler M. MRA: how it's done and what it shows. Diagn Imaging (San Franc). 1990 Jun; 12(6):117, 120-5. PMID: 10149368.
      View in: PubMed
    115. Hylton NM, Chung WS, Botvinick EH, Schiller NB, Sheldon P, Kaufman L. Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries. J Digit Imaging. 1990 Feb; 3(1):34-7. PMID: 2092801.
      View in: PubMed
    116. Hylton N. Characterization of arterial blood flow using magnetic resonance imaging techniques. Monogr Atheroscler. 1990; 15:32-42. PMID: 2296250.
      View in: PubMed
    117. Crooks LE, Arakawa M, Hylton NM, Avram H, Hoenninger JC, Watts JC, Hale JD, Kaufman L. Echo-planar pediatric imager. Radiology. 1988 Jan; 166(1 Pt 1):157-63. PMID: 3336674.
      View in: PubMed
    118. Mills TC, Ortendahl DA, Hylton NM, Crooks LE, Carlson JW, Kaufman L. Partial flip angle MR imaging. Radiology. 1987 Feb; 162(2):531-9. PMID: 3797669.
      View in: PubMed
    119. Crooks LE, Hylton NM, Ortendahl DA, Posin JP, Kaufman L. The value of relaxation times and density measurements in clinical MRI. Invest Radiol. 1987 Feb; 22(2):158-69. PMID: 3557889.
      View in: PubMed
    120. Ortendahl DA, Posin JP, Hylton N, Mills CM. Optimal visualization of the cerebrospinal fluid on MRI. AJNR Am J Neuroradiol. 1986 May-Jun; 7(3):403-7. PMID: 3085445.
      View in: PubMed
    121. Hylton NM, Ortendahl DA. Information processing in magnetic resonance imaging. Crit Rev Diagn Imaging. 1986; 26(4):325-58. PMID: 3545683.
      View in: PubMed
    122. Posin JP, Ortendahl DA, Hylton NM, Kaufman L, Watts JC, Crooks LE, Mills CM. Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions. Radiology. 1985 Jun; 155(3):719-25. PMID: 4001375.
      View in: PubMed
    123. Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Watts JC, Kaufman L, Arakawa M, Hoenninger JC. Multiple spin-echo magnetic resonance imaging. Radiology. 1985 May; 155(2):437-42. PMID: 3983396.
      View in: PubMed
    124. Ortendahl DA, Hylton N, Kaufman L, Watts JC, Crooks LE, Mills CM, Stark DD. Analytical tools for magnetic resonance imaging. Radiology. 1984 Nov; 153(2):479-88. PMID: 6091173.
      View in: PubMed
    125. Ortendahl DA, Hylton NM, Kaufman L, Crooks LE. Signal to noise in derived NMR images. Magn Reson Med. 1984 Sep; 1(3):316-38. PMID: 6571562.
      View in: PubMed
    126. Brant-Zawadzki M, Bartkowski HM, Ortendahl DA, Pitts LH, Hylton NM, Nishimura MC, Crooks LE. NMR in experimental cerebral edema: value of T1 and T2 calculations. AJNR Am J Neuroradiol. 1984 Mar-Apr; 5(2):125-9. PMID: 6422714.
      View in: PubMed
    Nola's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP